Fountas A, et al. - Researchers conducted a systematic review of published literature reporting on silent corticotroph adenoma (SCA) outcomes up to October 31, 2017, to determine recurrence rates of SCAs after primary treatment (surgery followed, or not, by radiotherapy) and recurrence rate ratios (RRRs) between SCAs and other nonfunctioning pituitary adenoma (NFPA) subtypes. Based on mean follow-up studies ≥5 years, 31% of SCAs are recurring. No evidence was found to support a higher risk of SCAs recurrence compared to other NFPA subtypes. No significant RRR was also revealed by focusing on tumors treated solely by surgery.